Abiraterone-based triplet boosts survival in de novo mCSPC

Median time from diagnosis was 2.2 (IQR, 1.6-3.0) in the SOC +/- RXT + abiraterone arm and 2.2 (IQR, 1.4-2.9) in the SOC +/- RXT arm.
(Orginal – Story lesen…)